EFA vs IBB
iShares MSCI EAFE ETF vs iShares Biotechnology ETF
- • EFA has the lower expense ratio at 0.32% vs 0.44% for IBB.
- • EFA pays a higher dividend yield (3.26%).
Side-by-side metrics
| Metric | EFA | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.32% | 0.44% |
Dividend yield Trailing 12-month yield. | 3.26% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $76.62B | $11.50B |
YTD return | 11.02% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 0.60 |
P/E ratio | 17.37 | 25.48 |
Last price | $104.61 | $217.75 |
Inception | — | — |
Issuer | iShares | iShares |
EFA top holdings
| ASML.AS | ASML Holding NV | 2.86% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 1.60% |
| SHEL.L | Shell PLC | 1.46% |
| NOVN.SW | Novartis AG Registered Shares | 1.39% |
| HSBA.L | HSBC Holdings PLC | 1.37% |
| AZN.L | AstraZeneca PLC | 1.32% |
| NESN.SW | Nestle SA | 1.24% |
| SAP.DE | SAP SE | 1.11% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 1.09% |
| SIE.DE | Siemens AG | 1.00% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About EFA
EFA (iShares MSCI EAFE ETF) is Developed-market equities outside US/Canada. Managed by iShares, the fund carries $76.6B in assets under management, an expense ratio of 0.32%, a dividend yield of 3.26%. Its largest holding is ASML Holding NV (ASML.AS), which represents 2.9% of the portfolio. Real Estate is the fund's largest sector exposure at 1.6%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.